NanoViricides (NYSE:NNVC) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of NanoViricides (NYSE:NNVC) in a research note released on Monday morning. The firm issued a sell rating on the stock.

NanoViricides Trading Down 2.5 %

NYSE NNVC opened at $1.15 on Monday. The stock has a market cap of $13.55 million, a PE ratio of -1.42 and a beta of 0.67. NanoViricides has a twelve month low of $1.00 and a twelve month high of $2.00. The stock has a fifty day simple moving average of $1.22 and a 200-day simple moving average of $1.16.

NanoViricides (NYSE:NNVC) last released its quarterly earnings results on Wednesday, February 14th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01.

Hedge Funds Weigh In On NanoViricides

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in NanoViricides by 7.1% during the 3rd quarter. Vanguard Group Inc. now owns 458,072 shares of the company’s stock valued at $792,000 after acquiring an additional 30,194 shares during the period. Renaissance Technologies LLC boosted its holdings in NanoViricides by 72.2% during the 1st quarter. Renaissance Technologies LLC now owns 76,800 shares of the company’s stock valued at $161,000 after acquiring an additional 32,200 shares during the period. Millennium Management LLC boosted its holdings in NanoViricides by 59.1% during the 4th quarter. Millennium Management LLC now owns 67,346 shares of the company’s stock valued at $75,000 after acquiring an additional 25,012 shares during the period. Two Sigma Investments LP purchased a new position in NanoViricides during the 3rd quarter valued at about $59,000. Finally, UBS Group AG boosted its holdings in NanoViricides by 114.5% during the 1st quarter. UBS Group AG now owns 17,448 shares of the company’s stock valued at $37,000 after acquiring an additional 9,314 shares during the period. 10.30% of the stock is currently owned by hedge funds and other institutional investors.

About NanoViricides

NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.